Rezolute Inc faces significant decline amid market weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2024
0mins
Source: Coinmarketcap
Rezolute Inc's stock has dropped by 89.40% in pre-market trading, crossing below its 5-day SMA. This drastic decline comes as the broader market shows signs of weakness, with the Nasdaq-100 down 0.44% and the S&P 500 down 0.83%.
The significant drop in Rezolute's stock price is attributed to broad market weakness, as the overall sentiment in the market has shifted negatively. The stock's movement below the 5-day SMA indicates a bearish trend, reflecting investor concerns amid the declining indices.
This decline raises questions about the company's future performance and investor confidence, especially in a challenging market environment. Investors will be closely monitoring any developments that could impact Rezolute's position in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RZLT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RZLT
Wall Street analysts forecast RZLT stock price to rise
9 Analyst Rating
5 Buy
4 Hold
0 Sell
Moderate Buy
Current: 4.890
Low
2.00
Averages
6.29
High
20.00
Current: 4.890
Low
2.00
Averages
6.29
High
20.00
About RZLT
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rezolute to Present Research Findings at ENDO Conference
- Presentation Schedule: Rezolute will showcase four presentations at the Endocrine Society Annual Meeting from June 13-16, 2026, including an oral presentation by Dr. Huseyin Demirbilek, focusing on results from the sunRIZE study, highlighting the company's advancements in ultra-rare diseases.
- Research Findings Overview: The oral presentation will cover the application of Ersodetug in congenital hyperinsulinism, presenting top-line results from a multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trial, emphasizing the drug's potential in treating refractory hypoglycemia.
- Clinical Trial Participation: The sunRIZE study enrolled 63 participants across multiple countries to evaluate the efficacy of Ersodetug in patients aged 3 months to 45 years, and although it did not meet primary and key secondary endpoints, significant glycemic improvements were observed during the maintenance dosing phase compared to placebo.
- FDA Next Steps: Despite the study not meeting all expected metrics, the FDA encouraged Rezolute to submit comprehensive analysis datasets for independent evaluation, indicating a willingness from regulators to consider the potential value of the drug.
See More
ABIVAX and Others See Significant Stock Gains
- ABIVAX Clinical Trial Success: ABIVAX reported positive results from its Phase 3 ABTECT trial for Obefazimod in ulcerative colitis, achieving primary endpoint of clinical remission at Week 44 with both 25mg and 50mg doses, planning to submit a New Drug Application to the FDA in late Q4 2026, leading to a 24.34% stock increase to $90.15.
- Cingulate Faces FDA Challenge: Cingulate's stock rose 21.09% to $4.88 despite the FDA's rejection of its ADHD drug CTx-1301 application; however, with nearly $30 million in cash reserves, the company aims to resolve CMC issues and proceed with resubmission while continuing pre-commercial activities.
- Alpha Tau Partners with Tolmar: Alpha Tau entered a strategic collaboration with Tolmar to develop and commercialize Alpha DaRT for prostate cancer in the U.S., with Tolmar investing $15 million upfront and $20 million equity stake, while Alpha Tau retains manufacturing rights, resulting in an 18.48% stock increase to $10.58.
- MiniMed Strong Financial Results: MiniMed reported worldwide net sales of $3.102 billion for FY 2026, a 14.2% increase, and expects around 10% organic revenue growth for FY 2027, reflecting strong international market performance and new product launches, with stock rising 15.94% to $14.26.
See More
Rezolute Stock Rises Following Upgrade by Citizens JMP Securities
- Stock Upgrade Impact: Rezolute (RZLT) traded higher for the third consecutive session on Wednesday after Citizens JMP Securities upgraded its rating from Market Perform to Market Outperform, reflecting a positive market sentiment towards the company's future prospects.
- Clinical Trial Progress: The company's interim data from the upLIFT Phase 3 study for its lead asset, ersodetug, in tumor hyperinsulinism, released on Tuesday, triggered nearly an 11% stock price increase, showcasing the drug's potential in the rare disease space.
- FDA Approval Outlook: Analyst Jason Butler noted that the approval pathway for ersodetug in tumor hyperinsulinism could be distinct from the setbacks faced last year in congenital hyperinsulinism, providing confidence for FDA approval with a target price set at $11.
- Positive Market Reaction: The stock's rise due to favorable clinical data and the analyst's optimistic rating indicates that investors are increasingly confident in the company's potential success in treating rare diseases, likely attracting more investor interest.
See More
Wall Street's Latest Ratings Overview
- DigitalOcean Coverage Initiated: KeyBanc initiates coverage of DigitalOcean with an Overweight rating and a $200 price target, indicating significant room for expansion in the cloud computing market, which could enhance its growth trajectory.
- Omnicom Growth Outlook: Goldman Sachs rates Omnicom as a Buy, highlighting an 18% free cash flow yield and organic growth in its core business, suggesting it will outperform consensus EBIT and FCF estimates, reflecting strong performance in the advertising sector.
- SSR Mining Upgrade: RBC upgrades SSR Mining from Sector Perform to Outperform, citing strategic transactions that have reduced jurisdictional risk and exceptional financial liquidity, with cash representing one-third of market cap, indicating robust future growth potential.
- Apple's Positive Outlook: Goldman Sachs reiterates a Buy rating on Apple, anticipating the announcement of an AI-enhanced Siri at the upcoming Worldwide Developers Conference, which will include several delayed features, showcasing Apple's ongoing innovation in AI technology.
See More
Rezolute Updates Late-Stage Trial Progress for Ersodetug
- Participant Progress: Rezolute has enrolled 8 patients in its upLIFT Phase 3 study, with 6 achieving the necessary level to measure the trial's primary endpoint, indicating treatment efficacy and laying a foundation for future market potential.
- Significant Treatment Effects: All 6 participants discontinued intravenous glucose requirements after therapy, demonstrating positive outcomes in addressing hypoglycemia, which may attract increased investor interest.
- Good Safety Profile: The company reported no safety concerns during the pivotal and extension phases of the study, enhancing confidence in the therapy and potentially accelerating subsequent regulatory approval processes.
- Data Release Timeline: The upLIFT trial has reached 50% of its enrollment target, with topline data expected to be reported in H2 2026, further advancing the company's strategic positioning in the rare disease treatment space.
See More
Rezolute Reports Q3 Earnings Beat Expectations
- Earnings Beat: Rezolute reported a Q3 GAAP EPS of -$0.16, beating expectations by $0.02, indicating a slight improvement in financial performance despite remaining in a loss position.
- Cash Position: As of March 31, 2026, the company had $120.3 million in cash, cash equivalents, and marketable securities, down from $167.9 million as of June 30, 2025, reflecting pressure on the company's financial management.
- FDA Meeting Feedback: Despite receiving positive feedback from the FDA meeting, the market remains cautious about the prospects of its lead asset, leading analysts to maintain a
See More
Rezolute to Present Research Findings at ENDO Conference
- Presentation Schedule: Rezolute will showcase four presentations at the Endocrine Society Annual Meeting from June 13-16, 2026, including an oral presentation by Dr. Huseyin Demirbilek, focusing on results from the sunRIZE study, highlighting the company's advancements in ultra-rare diseases.
- Research Findings Overview: The oral presentation will cover the application of Ersodetug in congenital hyperinsulinism, presenting top-line results from a multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trial, emphasizing the drug's potential in treating refractory hypoglycemia.
- Clinical Trial Participation: The sunRIZE study enrolled 63 participants across multiple countries to evaluate the efficacy of Ersodetug in patients aged 3 months to 45 years, and although it did not meet primary and key secondary endpoints, significant glycemic improvements were observed during the maintenance dosing phase compared to placebo.
- FDA Next Steps: Despite the study not meeting all expected metrics, the FDA encouraged Rezolute to submit comprehensive analysis datasets for independent evaluation, indicating a willingness from regulators to consider the potential value of the drug.
See More
ABIVAX and Others See Significant Stock Gains
- ABIVAX Clinical Trial Success: ABIVAX reported positive results from its Phase 3 ABTECT trial for Obefazimod in ulcerative colitis, achieving primary endpoint of clinical remission at Week 44 with both 25mg and 50mg doses, planning to submit a New Drug Application to the FDA in late Q4 2026, leading to a 24.34% stock increase to $90.15.
- Cingulate Faces FDA Challenge: Cingulate's stock rose 21.09% to $4.88 despite the FDA's rejection of its ADHD drug CTx-1301 application; however, with nearly $30 million in cash reserves, the company aims to resolve CMC issues and proceed with resubmission while continuing pre-commercial activities.
- Alpha Tau Partners with Tolmar: Alpha Tau entered a strategic collaboration with Tolmar to develop and commercialize Alpha DaRT for prostate cancer in the U.S., with Tolmar investing $15 million upfront and $20 million equity stake, while Alpha Tau retains manufacturing rights, resulting in an 18.48% stock increase to $10.58.
- MiniMed Strong Financial Results: MiniMed reported worldwide net sales of $3.102 billion for FY 2026, a 14.2% increase, and expects around 10% organic revenue growth for FY 2027, reflecting strong international market performance and new product launches, with stock rising 15.94% to $14.26.
See More
Rezolute Stock Rises Following Upgrade by Citizens JMP Securities
- Stock Upgrade Impact: Rezolute (RZLT) traded higher for the third consecutive session on Wednesday after Citizens JMP Securities upgraded its rating from Market Perform to Market Outperform, reflecting a positive market sentiment towards the company's future prospects.
- Clinical Trial Progress: The company's interim data from the upLIFT Phase 3 study for its lead asset, ersodetug, in tumor hyperinsulinism, released on Tuesday, triggered nearly an 11% stock price increase, showcasing the drug's potential in the rare disease space.
- FDA Approval Outlook: Analyst Jason Butler noted that the approval pathway for ersodetug in tumor hyperinsulinism could be distinct from the setbacks faced last year in congenital hyperinsulinism, providing confidence for FDA approval with a target price set at $11.
- Positive Market Reaction: The stock's rise due to favorable clinical data and the analyst's optimistic rating indicates that investors are increasingly confident in the company's potential success in treating rare diseases, likely attracting more investor interest.
See More
Wall Street's Latest Ratings Overview
- DigitalOcean Coverage Initiated: KeyBanc initiates coverage of DigitalOcean with an Overweight rating and a $200 price target, indicating significant room for expansion in the cloud computing market, which could enhance its growth trajectory.
- Omnicom Growth Outlook: Goldman Sachs rates Omnicom as a Buy, highlighting an 18% free cash flow yield and organic growth in its core business, suggesting it will outperform consensus EBIT and FCF estimates, reflecting strong performance in the advertising sector.
- SSR Mining Upgrade: RBC upgrades SSR Mining from Sector Perform to Outperform, citing strategic transactions that have reduced jurisdictional risk and exceptional financial liquidity, with cash representing one-third of market cap, indicating robust future growth potential.
- Apple's Positive Outlook: Goldman Sachs reiterates a Buy rating on Apple, anticipating the announcement of an AI-enhanced Siri at the upcoming Worldwide Developers Conference, which will include several delayed features, showcasing Apple's ongoing innovation in AI technology.
See More
Rezolute Updates Late-Stage Trial Progress for Ersodetug
- Participant Progress: Rezolute has enrolled 8 patients in its upLIFT Phase 3 study, with 6 achieving the necessary level to measure the trial's primary endpoint, indicating treatment efficacy and laying a foundation for future market potential.
- Significant Treatment Effects: All 6 participants discontinued intravenous glucose requirements after therapy, demonstrating positive outcomes in addressing hypoglycemia, which may attract increased investor interest.
- Good Safety Profile: The company reported no safety concerns during the pivotal and extension phases of the study, enhancing confidence in the therapy and potentially accelerating subsequent regulatory approval processes.
- Data Release Timeline: The upLIFT trial has reached 50% of its enrollment target, with topline data expected to be reported in H2 2026, further advancing the company's strategic positioning in the rare disease treatment space.
See More
Rezolute Reports Q3 Earnings Beat Expectations
- Earnings Beat: Rezolute reported a Q3 GAAP EPS of -$0.16, beating expectations by $0.02, indicating a slight improvement in financial performance despite remaining in a loss position.
- Cash Position: As of March 31, 2026, the company had $120.3 million in cash, cash equivalents, and marketable securities, down from $167.9 million as of June 30, 2025, reflecting pressure on the company's financial management.
- FDA Meeting Feedback: Despite receiving positive feedback from the FDA meeting, the market remains cautious about the prospects of its lead asset, leading analysts to maintain a
See More
